Bayer (0P6S) Receives a Buy from Goldman Sachs
Goldman Sachs analyst James Quigley maintained a Buy rating on Bayer today and set a price target of €54.50.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quigley covers the Healthcare sector, focusing on stocks such as Sanofi, Roche Holding AG, and Novo Nordisk. According to TipRanks, Quigley has an average return of -7.2% and a 39.49% success rate on recommended stocks.
In addition to Goldman Sachs, Bayer also received a Buy from Barclays’s Charles Pitman CFA in a report issued today. However, on the same day, DZ BANK AG downgraded Bayer (LSE: 0P6S) to a Sell.
0P6S market cap is currently €45.18B and has a P/E ratio of -228.21.
Read More on GB:0P6S:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.